Drug intelligence / Profile preview

Smallpox Biodefense Therapeutic

Development stage: Unknown
Lead developer: BioFactura
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Oral, Intravenous, Intramuscular, Topical

Overview

Smallpox Biodefense Therapeutic is a monoclonal antibody-based drug developed by BioFactura. It is being advanced under a contract with the Biomedical Advanced Research and Development Authority (BARDA) to address the threat of smallpox, whether from bioterrorism or accidental release. This therapeutic is intended to serve as a second antiviral option with a distinct mechanism of action, complementing the existing FDA-approved antiviral TPOXX, thereby bolstering national biodefense preparedness and mitigating potential viral resistance.

Targets

B5R (Vaccinia virus extracellular enveloped virion protein B5)Orthopoxvirus mature virion surface antigens

Beyond the preview

Go deeper on Smallpox Biodefense Therapeutic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Smallpox Biodefense Therapeutic.

Explore the full profile